Skip to main content

Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
T cell injection targeting CD7 chimeric antigen receptorN/A1 trial
Active Trials
NCT06871644Not Yet Recruiting18Est. Mar 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
BioTherapeutics IncT cell injection targeting CD7 chimeric antigen receptor

Clinical Trials (1)

Total enrollment: 18 patients across 1 trials

NCT06871644BioTherapeutics IncT cell injection targeting CD7 chimeric antigen receptor

Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases

Start: Mar 2025Est. completion: Mar 202718 patients
N/ANot Yet Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.